Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 23

Related Articles by Review for PubMed (Select 23559882)

1.

Overall survival should be the primary endpoint in clinical trials for advanced non-small-cell lung cancer.

Cheema PK, Burkes RL.

Curr Oncol. 2013 Apr;20(2):e150-60. doi: 10.3747/co.20.1226.

2.
3.

Issues surrounding clinical trial endpoints in solid malignancies with a focus on metastatic non-small cell lung cancer.

Garon EB.

Lung Cancer. 2012 Sep;77(3):475-81. doi: 10.1016/j.lungcan.2012.06.007. Epub 2012 Jul 12. Review.

4.

Current and emerging therapies for patients with advanced non-small-cell lung cancer.

Sheth S.

Am J Health Syst Pharm. 2010 Jan 1;67(1 Suppl 1):S9-14. doi: 10.2146/ajhp090457. Review.

PMID:
20044378
5.

Pemetrexed for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer.

Greenhalgh J, McLeod C, Bagust A, Boland A, Fleeman N, Dundar Y, Oyee J, Dickson R, Davis H, Green J, McKenna E, Pearson M.

Health Technol Assess. 2010 Oct;14(Suppl. 2):33-9. doi: 10.3310/hta14suppl2/05. Review.

6.

Smoking history as a predictive factor of treatment response in advanced non-small-cell lung cancer: a systematic review.

Mitchell P, Mok T, Barraclough H, Strizek A, Lew R, van Kooten M.

Clin Lung Cancer. 2012 Jul;13(4):239-51. doi: 10.1016/j.cllc.2011.08.003. Epub 2011 Dec 6. Review.

PMID:
22154074
7.

Should progression-free survival be the primary measure of efficacy for advanced NSCLC therapy?

Soria JC, Massard C, Le Chevalier T.

Ann Oncol. 2010 Dec;21(12):2324-32. doi: 10.1093/annonc/mdq204. Epub 2010 May 23. Review.

8.

Progression-free survival as surrogate and as true end point: insights from the breast and colorectal cancer literature.

Saad ED, Katz A, Hoff PM, Buyse M.

Ann Oncol. 2010 Jan;21(1):7-12. doi: 10.1093/annonc/mdp523. Epub 2009 Nov 9. Review.

9.

Targeted therapy for advanced renal cell cancer (RCC): a Cochrane systematic review of published randomised trials.

Coppin C, Kollmannsberger C, Le L, Porzsolt F, Wilt TJ.

BJU Int. 2011 Nov;108(10):1556-63. doi: 10.1111/j.1464-410X.2011.10629.x. Epub 2011 Sep 27. Review.

PMID:
21952069
10.

The role of EGFR tyrosine kinase inhibitors in the first-line treatment of advanced non small cell lung cancer patients harboring EGFR mutation.

Sgambato A, Casaluce F, Maione P, Rossi A, Rossi E, Napolitano A, Palazzolo G, Bareschino MA, Schettino C, Sacco PC, Ciadiello F, Gridelli C.

Curr Med Chem. 2012;19(20):3337-52. Review.

PMID:
22664249
11.

The use of irinotecan, oxaliplatin and raltitrexed for the treatment of advanced colorectal cancer: systematic review and economic evaluation.

Hind D, Tappenden P, Tumur I, Eggington S, Sutcliffe P, Ryan A.

Health Technol Assess. 2008 May;12(15):iii-ix, xi-162. Review.

12.

Postprogression survival for first-line chemotherapy of patients with advanced non-small-cell lung cancer.

Hayashi H, Okamoto I, Morita S, Taguri M, Nakagawa K.

Ann Oncol. 2012 Jun;23(6):1537-41. doi: 10.1093/annonc/mdr487. Epub 2011 Oct 29. Review.

13.

Overview of the current status of human epidermal growth factor receptor inhibitors in lung cancer.

Herbst RS, Sandler AB.

Clin Lung Cancer. 2004 Dec;6 Suppl 1:S7-S19. Review.

PMID:
15638959
14.

Targeted therapies for non-small cell lung cancer.

Dempke WC, Suto T, Reck M.

Lung Cancer. 2010 Mar;67(3):257-74. doi: 10.1016/j.lungcan.2009.10.012. Epub 2009 Nov 14. Review.

PMID:
19914732
15.

Current treatments for advanced stage non-small cell lung cancer.

Stinchcombe TE, Socinski MA.

Proc Am Thorac Soc. 2009 Apr 15;6(2):233-41. doi: 10.1513/pats.200809-110LC. Review.

PMID:
19349493
16.

Vandetanib: An overview of its clinical development in NSCLC and other tumors.

Morabito A, Piccirillo MC, Costanzo R, Sandomenico C, Carillio G, Daniele G, Giordano P, Bryce J, Carotenuto P, La Rocca A, Di Maio M, Normanno N, Rocco G, Perrone F.

Drugs Today (Barc). 2010 Sep;46(9):683-98. doi: 10.1358/dot.2010.46.9.1516989. Review.

PMID:
20967300
17.

Targeted therapy in non-small-cell lung cancer--is it becoming a reality?

Janku F, Stewart DJ, Kurzrock R.

Nat Rev Clin Oncol. 2010 Jul;7(7):401-14. doi: 10.1038/nrclinonc.2010.64. Epub 2010 Jun 15. Review. Erratum in: Nat Rev Clin Oncol. 2011 Jul;8(7):384.

PMID:
20551945
18.

Recent issues in first-line treatment of advanced non-small-cell lung cancer: Results of an International Expert Panel Meeting of the Italian Association of Thoracic Oncology.

Gridelli C, Ardizzoni A, Douillard JY, Hanna N, Manegold C, Perrone F, Pirker R, Rosell R, Shepherd FA, De Petris L, Di Maio M, de Marinis F.

Lung Cancer. 2010 Jun;68(3):319-31. doi: 10.1016/j.lungcan.2009.11.018. Epub 2009 Dec 24. Review.

PMID:
20036027
19.

Efficacy and safety of vandetanib, a dual VEGFR and EGFR inhibitor, in advanced non-small-cell lung cancer: a systematic review and meta-analysis.

Zhang X, Qin Y, Li H, Bai C, Zhu T, Xu J, Wu C, Wu M, Wang C, Song H, Wei L, He J.

Asian Pac J Cancer Prev. 2011;12(11):2857-63. Review.

20.
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk